Cancer / Immunology
Novartis Review Reveals Fear of Recurrence as a Major Unmet Need in Breast Cancer Survivorship Across Asia Pacific and the Middle East
A new targeted literature review finds the fear of recurrence a major unmet need in breast cancer survivorship, often found to affect at least two in fiv...
October 31, 2025 | Report
Myrio Therapeutics Partners with University of Pennsylvania and NYU Langone to Advance Next-Generation T Cell Immunotherapies
Myrio Therapeutics, the University of Pennsylvania Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to...
October 29, 2025 | News
SimplyTest Launches Saliva-Based Oral HPV Test to Transform Early Detection of Oropharyngeal Cancers
SimplyTest® has launched a groundbreaking saliva-based test to detect high-risk strains of oral human papillomavirus (HPV), a major cause of oropharyng...
October 29, 2025 | News
OncoC4 and BioNTech’s Gotistobart Receives Breakthrough Therapy Designation in China for Squamous Non-Small Cell Lung Cancer
Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype...
October 28, 2025 | News
Kazia Therapeutics Seeks FDA Guidance on Paxalisib Survival Data in Glioblastoma Under Project FrontRunner Framework
Kazia Therapeutics Limited ("Kazia" or the "Company")announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug A...
October 28, 2025 | News
Vinmec Hospital’s AIET Cell Therapy Extends Survival and Quality of Life for Cancer Patients, Elevating Vietnam’s Role in Asian Medical Tourism
Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy...
October 28, 2025 | News
Singapore Approves Pfizer-BioNTech’s LP.8.1-Adapted COVID-19 Vaccine for Individuals Aged Six Months and Older
The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinic...
October 27, 2025 | News
BioMed X and Daiichi Sankyo Launch New Research Team in Heidelberg to Advance Multispecific Biologics for Solid Tumour Immunotherapy
BioMed X, a leading innovation hub for pharma,announced the start of a new research team at its Heidelberg institute for multispecific biologics in th...
October 24, 2025 | News
ACM Biolabs and National Cancer Centre Singapore Report Encouraging Asia-Based Early Clinical Findings for ACM-CpG Nanoparticle Immunotherapy
ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, announced encouraging early clinica...
October 23, 2025 | News
AdvanCell’s Lead-212 Radioligand Therapy Shows Strong Safety and Efficacy in Phase 1b Trial for Metastatic Prostate Cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastat...
October 22, 2025 | News
PeptiDream, PDRadiopharma, and Curium Launch Registrational Phase 2 Trial in Japan for 64Cu-PSMA-I&T Targeting Prostate Cancer
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), PDRadiopharm...
October 17, 2025 | News
Jacobio Pharma Partners with Oceanpine Capital in RMB 200 Million Equity Deal for Cardiovascular Research Subsidiary
Jacobio Pharma announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity...
October 16, 2025 | News
Everest Medicines Secures Dual IND Approvals for EVM14, Its First Internally Developed Therapeutic mRNA Cancer Vaccine
EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medic...
October 14, 2025 | News
Henlius’ HANSIZHUANG Meets Primary Endpoint in Phase 3 Gastric Cancer Trial
The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Applicati...
October 13, 2025 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
